Recent Updates — PROF
Profound Medical Corp. issued a press release announcing that five abstracts related to its TULSA-PRO system were presented at the 15th Interventional MRI Symposium in Boston. The presentations highlight real-world performance data from the CARE Registry and Mayo Clinic, clinical differentiation results from the CAPTAIN randomized controlled trial comparing TULSA to robotic radical prostatectomy, and technical validation of the procedure on a lower-field-strength Siemens MRI platform. These findings aim to strengthen evidence supporting the system's safety, efficacy, and potential for broader adoption. Profound Medical Corp. is a commercial-stage medical device company that develops interventional MRI technologies, including the TULSA-PRO system for prostate ablation and Sonalleve for non-surgical therapy of various conditions.
Profound Medical Corp. entered into a co-education agreement with Telix Pharmaceuticals Limited to educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO platform. The collaboration aims to increase physician awareness, support patient selection, and expand access to the TULSA Procedure through scientific meetings, speaker programs, and educational content. Profound plans to develop PSMA-PET–MR image-fusion capabilities for its Treatment Delivery Console software to enhance treatment planning precision. Profound Medical Corp. is a commercial-stage medical device company that develops and markets innovative interventional MRI procedures.
Profound Medical Corp. issued preliminary unaudited financial results for the third quarter ended September 30, 2026, anticipating total revenue between $9.8 million and $10.0 million. This range represents approximately 85% to 89% year-over-year growth compared to $5.3 million in Q3 2025 and roughly 292% to 300% sequential growth from $2.5 million in Q2 2026. The expected revenue exceeds the Bloomberg mean analyst consensus of $6.78 million by approximately 45% to 47%. Gross margin is also projected to exceed 70%. Full financial results will be reported after market close on November 5, 2026. Profound Medical Corp. is a commercial-stage medical device company that develops and markets innovative interventional MRI procedures for prostate care and other conditions.
Profound Medical Corp. appointed Richard R. Fabian as President, effective September 1, 2026, succeeding Mathieu Burtnyk, who transitioned to the newly created role of Chief Technology Officer. Mr. Fabian brings over 29 years of experience in healthcare executive management, most recently serving as CEO of FUJIFILM Sonosite and holding leadership roles at Philips Healthcare. His compensation package includes an annualized base salary of $550,000, a discretionary bonus potential of up to 100% of base salary, a monthly car allowance of $1,000, and a residence lease in Toronto for approximately half his time. He received 200,000 restricted share units vesting over three years and options for 475,000 common shares vesting over four years. Profound Medical Corp. is a commercial-stage medical device company that develops and markets innovative interventional MRI procedures.